Back to results
US 2020/0399316 A1Published application
Peptide conjugates
AssigneeBioniz, LLC
InventorsYutaka Tagaya, Nazli Azimi
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeBioniz, LLC
InventorsYutaka Tagaya, Nazli Azimi
Estimating the term…
Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
A nucleotide sequence encoding a therapeutic composite peptide, wherein the therapeutic composite peptide inhibits an activity of at least two cytokines selected from a family of cytokines that bind to a common receptor, and wherein the therapeutic composite peptide comprises a region 1-20 amino acids in length that aligns with a corresponding region of a single target ligand or receptor.
A pharmaceutical composition comprising:
A genetic construct comprising:
Dependencies are inferred from the claim text.